RA
ACLX

Rise Advisors’s Arcellx ACLX Stock Holding History

Rise Advisors’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7
Closed -$575 – 113
2025
Q3 		$575 Buy
+7
New +$504 ﹤0.01% 1379

Other funds holding ACLX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rise Advisors's ACLX Position: Q4 2025 in Review

Rise Advisors sold out of Arcellx (ACLX) in Q4 2025, closing a stake of 7 shares — an estimated $575 sold.

Rise Advisors first reported a position in ACLX in Q3 2025 and held it in 1 quarter. The position peaked at $575 in Q3 2025. 218 funds tracked by Wall St. Rank hold ACLX as of Q4 2025.

  • Rise Advisors reported no remaining Arcellx position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 7 Arcellx shares in Q4 2025, an estimated $575.
  • Rise Advisors first reported a position in Arcellx in Q3 2025 and held it in 1 quarter.
  • Rise Advisors's Arcellx position peaked at $575 in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Arcellx as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.